Genelux Corporation(GNLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GNLX Genelux Corporation

Trading 02-04 15:17:13 EST

2.60

-0.12

-4.41%

High2.70	Low2.46	Vol253.46K
Open2.70	D1 Closing2.72	Amplitude8.82%
Mkt Cap116.27M	Tradable Cap94.82M	Total Shares44.72M
T/O642.78K	T/O Rate0.70%	Tradable Shares36.47M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GNLX","market":"US","secType":"STK","nameCN":"Genelux Corporation","latestPrice":2.6,"timestamp":1770236223481,"preClose":2.72,"halted":0,"volume":253463,"delay":0,"changeRate":-0.04411764705882357,"floatShares":36467700,"shares":44718438,"eps":-0.878138,"marketStatus":"Trading","change":-0.12,"latestTime":"02-04 15:17:13 EST","open":2.7,"high":2.7,"low":2.46,"amount":642775.7553861,"amplitude":0.088235,"askPrice":2.61,"askSize":599,"bidPrice":2.59,"bidSize":198,"shortable":3,"etf":0,"ttmEps":-0.878138,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770238800000},"marketStatusCode":2,"adr":0,"listingDate":1674709200000,"exchange":"NASDAQ","adjPreClose":2.72,"preHourTrading":{"tag":"盘前","latestPrice":2.8,"preClose":2.72,"latestTime":"08:06 EST","volume":354,"amount":991.1199960000001,"timestamp":1770210403703,"change":0.08,"changeRate":0.029412,"amplitude":0.007353},"postHourTrading":{"tag":"盘后","latestPrice":2.7441,"preClose":2.72,"latestTime":"19:02 EST","volume":2808,"amount":7718.9135,"timestamp":1770163358961,"change":0.0241,"changeRate":0.00886,"amplitude":0.011029},"volumeRatio":1.633091,"impliedVol":0.3992,"impliedVolPercentile":0.1364},"requestUrl":"/m/hq/s/GNLX","defaultTab":"news","newsList":[{"id":"2603526821","title":"Genelux Executives Join Titan Partners for Virtual Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2603526821","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603526821?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:00","pubTimestamp":1768251609,"startTime":"0","endTime":"0","summary":"Genelux Corporation will participate in a virtual fireside chat hosted by Titan Partners on Monday, January 19, 2026, at 9:00 a.m. PT. The event will feature company executives, including President and CEO Thomas Zindrick, CFO Matt Pulisic, and Chief Medical Officer Dr. Jason Litten, discussing the company's latest developments. A live webcast will be available on the investor relations section of the Genelux website, with an archived replay accessible afterward.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLb8gBwy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD","GNLX","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4139","IE00BKPKM429.USD","BK4585","BK4112"],"gpt_icon":0},{"id":"2602397269","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2602397269","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602397269?lang=en_us&edition=fundamental","pubTime":"2026-01-09 03:37","pubTimestamp":1767901029,"startTime":"0","endTime":"0","summary":"CorMedix  reported Q4 preliminary net revenue on Thursday, a touch below the average analyst estimate compiled by FactSet, and its forecast range for full-year 2026 sales also missed consensus.Shares of the health care firm sank 33% following an increase in intraday trading volume to over 19 million from a daily average of about 2.78 million.Acuity  shares sank 14% after the lighting and building management solutions provider left its full-year adjusted earnings and sales outlook unchanged, taking the shine off its fiscal Q1 adjusted earnings beat.More than 822,000 shares of the company traded intraday compared with a daily average of about 249,000.Genelux  said Thursday it priced an underwritten public offering of about 6.67 million shares at $3 each, targeting gross proceeds of roughly $20.0 million.Shares of the biopharmaceutical company slumped 18% as intraday trading volume soared to over 1.23 million from a daily average of about 237,000.Price: 7.54, Change: -3.63, Percent Change","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AYI","BK4096","LU0203347892.USD","BK4007","GNLX","BK4139","CRMD","LU0203345920.USD","AYI.AU","BK7062","LU0054578231.USD"],"gpt_icon":0},{"id":"2601360289","title":"BRIEF-Genelux Corporation Announces Pricing Of $20.0 Million Underwritten Public Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2601360289","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601360289?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:21","pubTimestamp":1767882119,"startTime":"0","endTime":"0","summary":"BRIEF-Genelux Corporation Announces Pricing Of $20.0 Million Underwritten Public Offering Of Common StockJan 8 (Reuters) - Genelux Corp GNLX.O:GENELUX CORPORATION ANNOUNCES PRICING OF $20.0 MILLION UN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUAHWWYZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2601360535","title":"Genelux Corp - Prices Public Offering of 6,666,667 Shares of Common Stock at $3.00 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2601360535","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601360535?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:13","pubTimestamp":1767881619,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUAHWWYZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2601365840","title":"Genelux Shares Sink Following Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2601365840","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601365840?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:17","pubTimestamp":1767871020,"startTime":"0","endTime":"0","summary":"Shares of Genelux fell after the company said it had commenced a proposed underwritten public offering of its common stock.The stock declined 8.8% to $3.09 in premarket trading Thursday. Through Wednesday's close, shares are up 33% over the past year.The immuno-oncology company late Wednesday didn't disclose the number of shares it anticipates selling, or the pricing. All shares are being offered by Genelux, it said.The company added it expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering.Lucid Capital Markets is acting as the sole book-running manager for the proposed offering.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Genelux Shares Sink Following Proposed Public Offering","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2601214384","title":"Genelux Corporation Files Initial Statement of Beneficial Ownership for Chief Medical Officer Jason Litten","url":"https://stock-news.laohu8.com/highlight/detail?id=2601214384","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601214384?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:30","pubTimestamp":1767825054,"startTime":"0","endTime":"0","summary":"Genelux Corporation has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Jason Litten, the company’s Chief Medical Officer, as the reporting beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDLchkdPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Genelux Corporation Files Initial Statement of Beneficial Ownership for Chief Medical Officer Jason Litten","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2601389263","title":"Genelux Corporation Announces Proposed Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2601389263","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601389263?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:01","pubTimestamp":1767819660,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., Jan.  07, 2026  (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a pro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214887/0/en/Genelux-Corporation-Announces-Proposed-Public-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2601882369","title":"BRIEF-Genelux Corp Announces Interim Results From Ongoing Lung Cancer Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882369","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601882369?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:01","pubTimestamp":1767621671,"startTime":"0","endTime":"0","summary":"BRIEF-Genelux Corp Announces Interim Results From Ongoing Lung Cancer TrialsJan 5 (Reuters) - Genelux Corp GNLX.O:GENELUX CORP - ANNOUNCES INTERIM RESULTS FROM ONGOING LUNG CANCER TRIALSGENELUX- IN AD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60FA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2601988139","title":"Genelux- in Advanced or Metastatic Recurrent Nsclc, Observed Anti-Tumor Activity in Initial Dose Cohort & Olvi-Vec Generally Well Tolerated (Phase 2 Viro-25)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601988139","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601988139?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:03","pubTimestamp":1767618231,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60FA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2601388154","title":"Genelux Corp - Topline Data From Phase 3 Ovarian Cancer Trial (Onprime/Gog-3076) in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601388154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601388154?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:03","pubTimestamp":1767618231,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60FA:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2601881883","title":"Genelux Reports Promising Interim Results for Systemic Olvi-Vec in Lung Cancer Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2601881883","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601881883?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:00","pubTimestamp":1767618028,"startTime":"0","endTime":"0","summary":"Genelux Corporation has announced interim results from two ongoing clinical trials evaluating the systemic administration of Olvi-Vec in patients with progressive small cell lung cancer  and non-small cell lung cancer  following failure of prior platinum-based therapies. In the Phase 1b/2 SCLC trial, partial responses were observed in three out of nine patients, including two cases of significant tumor shrinkage in the highest dose cohort. The Phase 2 VIRO-25 trial in advanced or metastatic recurrent NSCLC showed initial anti-tumor activity, with Olvi-Vec generally well tolerated. Enrollment in both studies is ongoing, and additional data are anticipated throughout 2026. Topline results from a Phase 3 ovarian cancer trial are expected in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes onl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL9p1nYn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","LU2210149790.SGD","BK4139","BK4588","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","NDAQ","LU2210150020.SGD","LU2095319765.USD","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2600098085","title":"Genelux Corporation Announces New Compensation Terms for Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2600098085","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600098085?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:11","pubTimestamp":1767388280,"startTime":"0","endTime":"0","summary":"Genelux Corporation has announced new compensation terms for its recently appointed Chief Medical Officer, Dr. Jason Litten. Effective January 2, 2026, Dr. Litten will receive an annual base salary of $475,000 and will be eligible for a discretionary annual bonus of up to 40% of his base salary, contingent on performance goals set by the Board of Directors. He has also been granted an option to purchase 275,000 shares of the company’s common stock, vesting over four years, with accelerated vesting in the event of a change in control. In case of involuntary termination, Dr. Litten will be eligible for severance benefits, including up to 12 months of salary and COBRA health insurance, with enhanced terms if termination occurs around a change in control.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL6WpFnY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2600065489","title":"Genelux Names Jason Litten as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2600065489","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600065489?lang=en_us&edition=fundamental","pubTime":"2026-01-02 21:36","pubTimestamp":1767360987,"startTime":"0","endTime":"0","summary":"Genelux  said Friday that Jason Litten has been named chief medical officer, effective immediately.Litten most recently served as chief medical officer at Chimeric Therapeutics, the company said.Litten received an inducement award of a stock option to purchase 275,000 shares under the company's 2023 inducement plan, Genelux said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2600506305","title":"Press Release: Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2600506305","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600506305?lang=en_us&edition=fundamental","pubTime":"2026-01-02 21:00","pubTimestamp":1767358800,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., Jan. 02, 2026  --  Genelux Corporation , a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones.\"We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes,\" said Thomas Zindrick, President, CEO, and Chairman of the Board. \"He brings extensive experience in oncology drug development of innovative therapies, including a proven track record of leading complex programs from early development through late-stage trials. Jason's insight and disciplined approach to clinical execution will support our momentum as we approach key readouts in ovarian and lung cancer and work to unlock the full clinical and commercial potential of Olv","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","GNLX","BK4585","BK4099","BK4588","03160","TM","BK4139","BK4604"],"gpt_icon":0},{"id":"2588062099","title":"Genelux Director John Thomas Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588062099","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588062099?lang=en_us&edition=fundamental","pubTime":"2025-12-03 08:00","pubTimestamp":1764720057,"startTime":"0","endTime":"0","summary":"John Thomas, Director of Genelux Corporation, reported a disposal of common shares of Genelux Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL2N2mcx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Genelux Director John Thomas Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2586252292","title":"Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2586252292","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586252292?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:00","pubTimestamp":1764162000,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., Nov.  26, 2025  (GLOBE NEWSWIRE) -- Genelux Corporation  (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/26/3195094/0/en/Genelux-Corporation-to-Participate-in-a-Fireside-Chat-at-Piper-Sandler-37th-Annual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","GNLX","BK4139","LABU","XLV","BK4588","LU0029874061.USD","HCSG","LU0128526141.USD","BK4581","XBI","BK4585"],"gpt_icon":0},{"id":"2581887576","title":"Genelux Corp. (GNLX) Receives a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2581887576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581887576?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:16","pubTimestamp":1762532191,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer maintained a Buy rating on Genelux Corp. today and set a price target of $16.00. According to TipRanks, Messer is a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/genelux-corp-gnlx-receives-a-buy-from-lake-street-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/genelux-corp-gnlx-receives-a-buy-from-lake-street-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2581856250","title":"Immuno-oncology firm Genelux's Q3 net loss beats expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2581856250","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581856250?lang=en_us&edition=fundamental","pubTime":"2025-11-06 06:49","pubTimestamp":1762382985,"startTime":"0","endTime":"0","summary":"Immuno-oncology firm Genelux's Q3 net loss beats expectationsOverviewGenelux Q3 net loss of $7.95 mln beats analyst expectationsCompany has $21 mln in cash and investments, funding operations into Q3 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH1KQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2581702452","title":"Genelux Corporation posts Q3 net loss of $8.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581702452","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581702452?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:24","pubTimestamp":1762377897,"startTime":"0","endTime":"0","summary":"Genelux Corporation reported a net loss of $8.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $6.5 million, or $0.19 per share, in the same period in 2024. Research and development expenses increased to $4.7 million from $4.1 million, mainly due to higher stock compensation and clinical trial costs. General and administrative expenses rose to $3.5 million from $2.9 million, primarily driven by increased stock compensation and salaries. As of September 30, 2025, Genelux held $21.0 million in cash, cash equivalents, short-term investments, and restricted cash, with a projected cash runway into the third quarter of 2026. Key business developments include continued progress in the Olvi-Vec program for solid tumors, ongoing enrollment in the Phase 3 ovarian cancer trial with topline data expected in the second half of 2026, and advancing lung cancer studies with interim data updates anticipated in the fourth quarter of 2025 and throughout 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL543C0X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4112","LU0314104364.USD","GNLX","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","LU2095319765.USD","NDAQ"],"gpt_icon":0},{"id":"2581141088","title":"Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2581141088","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581141088?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:20","pubTimestamp":1762377600,"startTime":"0","endTime":"0","summary":"-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 -- -- ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3182008/0/en/Genelux-Corporation-Reports-Third-Quarter-2025-Financial-Results-and-Provides-General-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genelux.com","stockEarnings":[{"period":"1week","weight":-0.0811},{"period":"1month","weight":-0.4022},{"period":"3month","weight":-0.6531},{"period":"6month","weight":-0.1856},{"period":"1year","weight":-0.2295},{"period":"ytd","weight":-0.3761}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.012999},{"month":2,"riseRate":0.75,"avgChangeRate":0.341787},{"month":3,"riseRate":0.333333,"avgChangeRate":0.130752},{"month":4,"riseRate":0,"avgChangeRate":-0.216003},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.034852},{"month":6,"riseRate":0.666667,"avgChangeRate":0.036149},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058289},{"month":8,"riseRate":0.666667,"avgChangeRate":0.080908},{"month":9,"riseRate":1,"avgChangeRate":0.122082},{"month":10,"riseRate":0.666667,"avgChangeRate":0.291649},{"month":11,"riseRate":0,"avgChangeRate":-0.218784},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053731}],"exchange":"NASDAQ","name":"Genelux Corporation","nameEN":"Genelux Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Genelux Corporation(GNLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Genelux Corporation(GNLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Genelux Corporation,GNLX,Genelux Corporation股票,Genelux Corporation股票老虎,Genelux Corporation股票老虎国际,Genelux Corporation行情,Genelux Corporation股票行情,Genelux Corporation股价,Genelux Corporation股市,Genelux Corporation股票价格,Genelux Corporation股票交易,Genelux Corporation股票购买,Genelux Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Genelux Corporation(GNLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Genelux Corporation(GNLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction